Lack of evidence for KRAS oncogenic mutations in triple-negative breast cancer

BMC Cancer

Research Article

Vanessa de Luque¹  José Lozano²  Luís G Pérez-Rivas²  Elena Gallego³  Luís Vicioso³  Alfonso Sánchez-Muñoz⁴  Nuria Ribelles⁴  Emilio Alba⁴ 

[1] Laboratorio de Investigación Biomédica (LIB-IMABIS), Hospital Universitario Virgen de la Victoria, Campus de Teatinos s/n, 29010, Málaga, Spain;Laboratorio de Investigación Biomédica (LIB-IMABIS), Hospital Universitario Virgen de la Victoria, Campus de Teatinos s/n, 29010, Málaga, Spain;Dpto. de Biología Molecular y Bioquímica, Facultad de Ciencias, Universidad de Málaga, Campus de Teatinos s/n, 29071, Málaga, Spain;Servicio de Anatomía Patológica, Hospital Universitario Virgen de la Victoria, Campus de Teatinos s/n, 29010, Málaga, Spain;Laboratorio de Investigación Biomédica (LIB-IMABIS), Hospital Universitario Virgen de la Victoria, Campus de Teatinos s/n, 29010, Málaga, Spain;Servicio de Oncología Médica, Hospital Universitario Virgen de la Victoria, Campus de Teatinos s/n, 29010, Málaga, Spain;Laboratorio de Investigación Biomédica (LIB-IMABIS), Hospital Universitario Virgen de la Victoria, Campus de Teatinos s/n, 29010, Málaga, Spain;

关键词: Epidermal Growth Factor Receptor;    Cetuximab;    KRAS Mutation;    Epidermal Growth Factor Receptor Expression;    Panitumumab;   

DOI  :  10.1186/1471-2407-10-136

 received in 2009-12-11, accepted in 2010-04-13,  发布年份 2010

来源: Springer

【 摘 要 】

BackgroundMutational analysis of the KRAS gene has recently been established as a complementary in vitro diagnostic tool for the identification of patients with colorectal cancer who will not benefit from anti-epidermal growth factor receptor (EGFR) therapies. Assessment of the mutation status of KRAS might also be of potential relevance in other EGFR-overexpressing tumors, such as those occurring in breast cancer. Although KRAS is mutated in only a minor fraction of breast tumors (5%), about 60% of the basal-like subtype express EGFR and, therefore could be targeted by EGFR inhibitors. We aimed to study the mutation frequency of KRAS in that subtype of breast tumors to provide a molecular basis for the evaluation of anti-EGFR therapies.MethodsTotal, genomic DNA was obtained from a group of 35 formalin-fixed paraffin-embedded, triple-negative breast tumor samples. Among these, 77.1% (27/35) were defined as basal-like by immunostaining specific for the established surrogate markers cytokeratin (CK) 5/6 and/or EGFR. KRAS mutational status was determined in the purified DNA samples by Real Time (RT)-PCR using primers specific for the detection of wild-type KRAS or the following seven oncogenic somatic mutations: Gly12Ala, Gly12Asp, Gly12Arg, Gly12Cys, Gly12Ser, Gly12Val and Gly13Asp.ResultsWe found no evidence of KRAS oncogenic mutations in all analyzed tumors.ConclusionsThis study indicates that KRAS mutations are very infrequent in triple-negative breast tumors and that EGFR inhibitors may be of potential benefit in the treatment of basal-like breast tumors, which overexpress EGFR in about 60% of all cases.

【 授权许可】

Unknown   
© Sánchez-Muñoz et al; licensee BioMed Central Ltd. 2010. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.